Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EV/DNG vs Microgynon for OC-Associated FSD
NCT00764881Phase 3Completed
- Sponsor
- Bayer
- Start
- Jan 2009
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of estradiol valerate + dienogest in female sexual dysfunction (FSD) (2 arms), sponsored by Bayer. Primary endpoint: Female Sexual Function Index (Questions 1-6) at Cycle 6. Started Jan 2009; status: completed.
02
Drugs
estradiol valerate + dienogest
03
Conditions
female sexual dysfunction (FSD)
Beyond the preview
Go deeper on NCT00764881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00764881.